Literature DB >> 25174384

[Repair of bedsore over greater trochanter in paraplegic patients with rectus femoris island myocutaneous flap].

Zunjiang Zhao1, Baode Zhang1, Yong Liu1, Rongtao Zhang1, Qiguo Liang1, Yudong Hu1, Liangyuan Xu1, Xiukun Wang1.   

Abstract

OBJECTIVE: To observe the effect of rectus femoris island myocutaneous flap for repairing bedsores in III and IV phases at the femoral greater trochanter area as a result of paraplegia.
METHODS: Thirteen paraplegic patients who suffered bedsores in III and IV phases at the greater trochanter of femur area were hospitalized from July 2009 to June 2013. The bedsores ranged from 4.5 cm×4.0 cm to 10.0 cm× 9.0 cm in area. After debridement, the size of soft tissue defect ranged from 5.0 cm×4.5 cm to 10.5 cm×10.0 cm. Rectus femoris island myocutaneous flaps were used to repair these defects, with flap area ranging from 5.0 cm×5.0 cm to 11.0 cm×10.0 cm and muscular pedicle length ranging from 8 to 12 cm. The donor sites of muscular pedicle were closed by direct suture, while those resulted from forming myocutaneous flap were closed by the transplantation of autologous skin obtained from thigh.
RESULTS: Necrosis appeared at the edge of myocutaneous flap in one patient, and it was healed after dressing change. The other 12 myocutaneous flaps survived well. Patients were followed up for 2 to 30 months, and bedsore did not recur.
CONCLUSIONS: Rectus femoris island myocutaneous flap, with characteristics of reasonable design, large donor area, big rotation angle, and with wear-, tear-, and pressure-resistance, is suitable for repairing bedsores at III and IV phases at the greater trochanter of femur area in paraplegic patients.

Entities:  

Mesh:

Year:  2014        PMID: 25174384

Source DB:  PubMed          Journal:  Zhonghua Shao Shang Za Zhi        ISSN: 1009-2587


  1 in total

1.  Primary repair of a massive pressure ulcer on the hip: report of one case.

Authors:  Jinglei Tan; Caiqiang Chen; Mingshi Zhang
Journal:  Ann Transl Med       Date:  2018-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.